Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Sandoz enters global collaboration license agreement with Henlius to commercialize ipilimumab in multiple indications

May 6, 2025

Concentra Biosciences to Acquire Kronos Bio 

May 6, 2025

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

May 6, 2025

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific ADC Program

May 6, 2025

Mosaic Therapeutics in-licenses two clinical-stage oncology programs from Astex Pharmaceuticals

April 30, 2025

Halozyme Sues Merck for Patent Infringement over SC Keytruda Formulation

April 30, 2025

DAAN Biotherapeutics and GC Cell Sign Exclusive Technology Transfer Agreement for Tumor Antigen-Specific Antibody Sequence to Advance CAR-T and CAR-NK Cell Therapies

April 30, 2025

Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of TCR-NK Therapy ZI-MA4-1 Targeting Solid Tumours

April 30, 2025

Innate Pharma regains rights on CD123 targeting ANKET® and announces Sanofi’s intention to make a strategic investment in the Company

April 30, 2025

Veraxa and Voyager to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

April 30, 2025

FDA Approves Second Drug Product Manufacturing Facility for ADSTILADRIN® (nadofaragene firadenovec-vncg)

April 30, 2025

Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop a Multimodal Foundation Model in Oncology

April 30, 2025

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

April 30, 2025

Moffitt Cancer Center Announces Strategic Collaboration With Galapagos To Transform CAR T Manufacturing in the Southeast

April 30, 2025

Guardant Health and Pfizer to Develop and Commercialize New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform

April 30, 2025

Merck KGaA to Acquire SpringWorks Therapeutics

April 30, 2025

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Actinium-225

April 28, 2025

REVEAL GENOMICS, Ona Therapeutics Partner to Advance ADC Across Multiple Tumor Types

April 22, 2025

nference and BeiGene Collaborate to Drive New B-Cell Cancer Research

April 22, 2025

Sumitomo Pharma America enters into a CRADA with the NCI to Advance Clinical Understanding of Enzomenib

April 22, 2025

Epsilogen Announces Acquisition of TigaTx, Inc. to Create Pan-Isotype Cancer Antibody Company

April 16, 2025

Solu Therapeutics Closes $41M Series A Financing; First Patient Dosed in Ph 1 Trial of STX-0712 in Patients with CMML and Other Heme Malignancies

April 16, 2025

Scancell Holdings announces partnership with the NHS CVLP to fast-track access for NHS patients into 4th cohort of Ph 2 SCOPE study

April 15, 2025

OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

April 15, 2025

Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment

April 15, 2025
Page1 Page2 Page3 … Page26

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.